

CVC Working Group Monthly Meeting Minutes

Thursday, August 19, 2021

11am-12pm PT | 1-2pm CT | 2-3pm ET | 3-4pm AT

No	Description	Notes	Time
1	Welcome and Release Update	<p>Update and overview of latest CVC release (Version 1.1.13)</p> <ul style="list-style-type: none"> ● COVID-19 vaccine lot/expiry information up until August 19, 2021 ● All vaccine product lot/expiry information for July 2021 ● Updates to FSN/PT/Picklist terms for some international COVID-19 vaccines <p>Next CVC release target date (Version 1.1.14): September 29, 2021</p>	Taylor
2	COVID-19 Terminology Discussion	<p>2a. Overview of terminology for international COVID-19 vaccines not licensed in Canada created to date/under review</p> <ul style="list-style-type: none"> ● RFCs have been submitted for the following international COVID-19 vaccines: <ul style="list-style-type: none"> ○ COVID-19 COVAXIN: https://informs.infoway-inforoute.ca/browse/SCT-11995?filter=-2 ○ COVID-19 vaccine WIBP: https://informs.infoway-inforoute.ca/browse/SCT-11996?filter=-2 ○ COVID-19 mRNA CVnCoV : https://informs.infoway-inforoute.ca/browse/SCT-11994?filter=-2 ● RFCs have also been submitted to create concepts for the same COVID-19 vaccine product marketed under a different tradename internationally: <ul style="list-style-type: none"> ○ COMIRNATY (equivalent to the Pfizer COVID-19 vaccine): https://informs.infoway-inforoute.ca/browse/SCT-12103?filter=-2 ○ Spikevax (equivalent to the Moderna vaccine): https://informs.infoway-inforoute.ca/browse/SCT-12104?filter=-2 ● For more information, refer to terminology hierarchy below 	<p>Cam</p> <p>Linda (CHI)</p>

2b. Review of COVID-19 Vaccine Terminology Naming Conventions. Please submit feedback to Linda Parisien at Canada Health Infoway (lparisien@infoway-inforoute.ca).

- Proposal from Canada Health Infoway to develop a naming convention pattern unique to COVID-19 vaccines (Canadian and international) to include **vaccine technology**.
- For examples, please refer to the attached CVC Working Group Meeting Presentation (slides 5-8).

Proposed pattern for COVID-19 vaccines marketed in Canada, or about to be marketed in Canada:

- Include vaccine technology (spelled out in the FSN and abbreviated in PT). This already exists in some concepts (e.g. Pfizer, Moderna), but would be added to others where it does not exist.
- For trade names that do not already have “COVID-19” and “vaccine” in the name, this would be added to the FSN (e.g. with COVISHIELD)
- If group agrees, these changes would apply for the development of concepts (not already published) *and* CHI would review and edit already published trade name COVID-19 concepts where this information does not exist.

Question for Stakeholders: Any feedback or objections to this approach?

Proposed pattern for international COVID-19 vaccines - no Market Authorization Holder

- Include vaccine technology type in international COVID-19 vaccines (spelled out in FSN, abbreviated in PT)
- In some cases, vaccines have an alternate synonym (e.g. Sputnik V COVID-19 vaccine has an alternate name of COVID-19 Gam-Covid-Vac; source: <https://travel.gc.ca/travel-covid/travel-restrictions/covid-vaccinated-travellers-entering-canada>).

		<p>Questions for Stakeholders:</p> <ul style="list-style-type: none"> ● Any feedback or objections to this approach? ● Do we need an alternate synonym for these concepts? <p>Proposed pattern for international COVID-19 vaccines with no Tradename:</p> <ul style="list-style-type: none"> ● FSN: Manufacturer/MAH COVID-19 technology spelled out vaccine vaccine (real medicinal product) ● PT: PHAC Product Abbreviation Manufacturer/MAH technology abbreviated (if available) ● This would be relevant for the Sinopharm vaccine, for example. <p>Question for Stakeholders: any feedback or objections to this approach?</p> <p>2c. Is there a need to create COVID-19 vaccine booster dose concepts?</p> <ul style="list-style-type: none"> ● Consensus that a COVID-19 booster dose concept is not needed unless it is a new type of vaccine/formulation 	
3	Data modelling	<p>Supporting the same product with different DINs in the CVC</p> <ul style="list-style-type: none"> ● Thank you to those who submitted a response. Analysis by CVC in team in progress. 	Taylor
4	CVC Usage	<p>Current State</p> <ul style="list-style-type: none"> ● Since inception, there have been >85,000 calls of the CVC <ul style="list-style-type: none"> ○ For those identified, they include EMR vendors, Ontario & BC governments, many unidentified ○ Awareness of those who download the CVC is unknown ● Suggestion to collect user information <ul style="list-style-type: none"> ○ When a user wants to download the CVC, they will need to complete a short form indicating: full name, email address, company and sector ○ When a user wants to integrate with the CVC API, they will need to complete a short form, the first time, to download an API Key that can be 	Alicia

		<p>used for all subsequent API calls and will indicate: full name, email address, company and organization sector.</p> <ul style="list-style-type: none"> • Many organization sector options (refer to CVC Working Group Meeting Deck) • This initiative would require a new API where API key is required and transition of all users to that new API (dates TBD) <p>Question for stakeholders:</p> <ul style="list-style-type: none"> • General feedback on method of tracking CVC usage? • Any other organization sector options we should consider? • Recommended lead time to integrate an API key? • How should this be communicated? 	
5	Wrap up and Questions	<p>Next meeting</p> <ul style="list-style-type: none"> • Thursday, September 30th, 2021 at 2pm EST • Register in advance for this meeting: https://infoway-inforoute.zoom.us/j/8446121262 	Taylor

COVID-19 Terminology Hierarchy

